Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 6, 1996, Pages 613-623

  Engel, Georg ^a   Hofmann, Ute ^b   Heidemann, Hugo ^b   Cosme, Jose ^b   Eichelbaum, Michel ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYMETHYLPHENAZONE; 4 HYDROXYPHENAZONE; CYTOCHROME P450; DRUG METABOLITE; FLUVOXAMINE; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; NORPHENAZONE; PHENAZONE; SULFAPHENAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; OXIDATION; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRINE; AUTOANTIBODIES; BIOTRANSFORMATION; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MICROSOMES, LIVER;

EID: 0029683112     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90001-6     Document Type: Article

References (44)

1. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992;13: 434-9.
2. George J, Farrell GC. Role of human hepatic cytochromes P450 in drug metabolism and toxicity. Aust NZ J Med 1991;21:356-62.
3. Park BK. Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol 1982;14:631-51.
4. Vesell ES. The model drug approach in clinical pharmacology. Clin Pharmacol Ther 1991;50:239-48.
5. Vesell ES. The antipyrine test in clinical pharmacology: Conceptions and misconceptions. Clin Pharmacol Ther 1979;26:275-86.
6. Hartleb M. Drugs and the liver part II: the role of the antipyrine test in drug metabolism studies. Biopharm Drug Dispos 1991;12:559-70.
7. Eichelbaum M, Ochs HR, Robertz GM, Somogyi A. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. Arzneimittelforschung 1982;32:575-8.
8. Eichelbaum M, Bertilsson L, Säwe J. Antipyrine metabolism in relation to the polymorphic oxidation of sparteine and debrisoquine. Br J Clin Pharmacol 1983;15:317-21.
9. Teunissen MWE, Spoelstra P, Koch CW, Weeda B, Duyn WV, Janssens AR, et al. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol 1984;18:707-15.
10. 14C-antipyrine in man [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1976;293(suppl):R63.
11. Schüppel R. Die Stickstoffdemethylierung am Phenazon (Antipyrin). Naunyn Schmiedebergs Arch Pharmak exp Path 1966;255:71-2.
12. Brodie BB, Axelrod J. The fate of antipyrine in man. J Pharmacol Exp Ther 1950;98:97-104.
13. Yoshimura H, Shimeno H, Tsukamoto H. Metabolism of drugs; LIX: a new metabolite of antipyrine. Biochem Pharmacol 1968;17:1511-6.
14. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
15. Breimer DD, Schellens JHM. A "cocktail" strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990;11:223-5.
16. Meier PJ, Müller HK, Dick B, Meyer UA. Hepatic monooxygenase activities in subjects with genetic defect in drug oxidation. Gastroenterology 1983;85:682-92.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-75.
18. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993;43:120-6.
19. Engel G, Hofmann U, Eichelbaum M. A highly sensitive and specific gas chromatographic/tandem mass spectrometric method for the determination of trace amounts of antipyrine in biological material. J Chromatogr B 1995;666:111-6.
20. Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Büschenfelde KH, Meyer UA, et al. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 1990;12:127-32.
21. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-endoplasmatic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987;84:551-5.
22. Meier UT, Meyer UA. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase: studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry 1987;26: 8466-74.
23. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990;252:442-7.
24. Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS. Purification and characterization of liver microsomal cytochrome P450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or naphthoflavone. Biochemistry 1982;21:6019-30.
25. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J. Furafyllin is a potent and selective inhibitor of cytochrome P450 I A 2 in man. Br J Clin Pharmacol 1990;29:651-63.
26. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45: 1211-4.
27. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988;26:23-9.
28. Maurice M, Pichard L, Dujat M, Fabre I, Joyeux H, Domergue J, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992;6:752-8.
29. Atiba JO, Blaschke TF, Wilkinson GR. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol 1989;28:161-5.
30. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989;28:166-70.
31. Eugster HP, Sengstag C. Saccharomyces cerevisiae: an alternative source for human liver microsomal liver enzymes and its use in drug interaction studies. Toxicology 1993;82:61-73.
32. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
33. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′- hydroxylation. Arch Bioehem Biophys 1993;306:240-5.
34. Srivastava PK, Yun CH, Beaune P, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450. Mol Pharmacol 1991; 40:69-79.
35. Gautier JC, Urban P, Beaune P, Pompon D. Engineered yeast cells as model to study coupling between human xenobiotic metabolizing enzymes. Eur J Biochem 1993;211:63-72.
36. Cullin C, Pompon D. Synthesis of functional mouse cytochrome P-450 P1 and chimeric P-450 P3-1 in the yeast Saccharomyces cerevisiae. Gene 1988;65:203-17.
37. Schellens JHM, van der Wart JHF, Danhof M, van der Velde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbitone, and theophylline in man as assessed by a "cocktail" approach. Br J Clin Pharmacol 1988;26:373-84.
38. Danhof M, Zuilen AV, Boeijinga JK, Breimer DD. Studies of the different metabolic pathways of antipyrine in man. Eur J Clin Pharmacol 1982;21:433-41.
39. Kahn GC, Boobis AR, Blair IA, Brodie MJ, Davies DS. A radiometric high pressure liquid chromatography assay for the simultaneous determination of the three main oxidative metabolites of antipyrine in studies in vitro. Anal Biochem 1981;113:292-300.
40. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors-evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-8.
41. Beaune P, Bourdi M, Belloc C, Gautier JC, Guengerich FP, Valadon P. Immunotoxicology and expression of human cytochrome P450 in microorganisms. Toxicology 1993;82:53-60.
42. Shimada F, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
43. Toverud EL, Boobis MJ, Murray S, Bennett PN, Whitmarsh V, Davies DS. Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol 1981;21:155-60.
44. Teunissen MWE, Bakker W, Meerburg-van der Torren JE, Breimer DD. Influence of rifampicin treatment of antipyrine clearance and metabolite formation in patients with tuberculosis. Br J Clin Pharmacol 1984;18:701-6.